[Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Context:

• Investigating a novel cancer immunotherapy targeting the human telomerase reverse transcriptase (hTERT) antigen.
• hTERT peptides are presented by MHC class I molecules on tumor cells, inducing cytotoxic T-lymphocyte (CTL) responses.
• Previous studies show TERT-specific CTLs can eliminate various hTERT-positive tumor cells.

Purpose:

• To evaluate the safety and efficacy of hTERT-based immunotherapy.
• To determine if hTERT-specific CTLs target tumor cells without harming essential normal cells.
• To assess the potential for hTERT-based therapies in clinical settings.

Summary:

• Antigen peptides from hTERT are expressed on tumor cells and elicit ex vivo CTL responses.
• TERT-specific CTLs kill hTERT-positive tumor cells in a MHC-restricted manner.
• Crucially, these CTLs do not lyse normal cells like hematopoietic progenitor cells or activated T-lymphocytes where telomerase is also detected.

Impact:

• Phase I clinical trials in advanced cancer patients demonstrated minimal impact on autoimmunity.
• These findings support the potential for broad-spectrum immunotherapy or immunoprevention strategies targeting hTERT.
• This research opens avenues for developing new cancer treatments with improved safety profiles.